• In February 2026, Nuvation Bio announced that its global SIGMA (G203) study of safusidenib for IDH1‑mutant astrocytoma had been expanded into a Phase 3 maintenance trial, broadening eligibility to grades 2–4 high‑risk tumors after standard treatment and increasing planned enrollment from 100 to 300 patients across the U.S., Australia and China.
• The amended protocol also adds a non‑pivotal, single‑arm cohort in chemotherapy‑ and radiotherapy‑naïve grade 3 IDH1‑mutant oligodendroglioma, which could clarify safusidenib’s role earlier in the treatment course for adult glioma patients facing currently incurable disease.
• Next, we’ll examine how expanding safusidenib’s SIGMA trial into a Phase 3 registration‑oriented program could influence Nuvation Bio’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Nuvation Bio Investment Narrative Recap

To own Nuvation Bio, you need to believe IBTROZI can fund the business while safusidenib becomes a genuine second pillar in IDH1‑mutant glioma. Expanding SIGMA into a Phase 3 maintenance trial sharpens that second‑pillar story but does not change the near term focus on IBTROZI uptake and execution, or the timing risk tied to a pivotal readout expected years away.

The February 2026 SIGMA update sits alongside January’s global taletrectinib collaboration with Eisai, which brought Nuvation Bio an upfront ~US$60,000,000 plus up to ~US$170,000,000 in milestones. Together, stronger IBTROZI economics and a clearer registrational path for safusidenib frame the key catalysts as commercial traction in ROS1 lung cancer and steady progress in a long, complex brain tumor program.

Yet beneath this progress, investors should also be aware that...

Nuvation Bio’s narrative projects $427.2 million revenue and $5.2 million earnings by 2028. This requires 151.8% yearly revenue growth and a roughly $222.7 million earnings increase from -$217.5 million today.

Uncover how Nuvation Bio's forecasts yield a $10.25 fair value, a 77% upside to its current price.

Exploring Other Perspectives

Before this SIGMA expansion, the most optimistic analysts were modeling revenue reaching about US$522,300,000 and earnings of roughly US$38,000,000 by 2028, which is far more upbeat than consensus. If you are weighing that view against the long trial timelines and competitive risks around safusidenib, this new Phase 3 design could strengthen or weaken those assumptions, so it is worth comparing several viewpoints rather than relying on a single narrative.

Explore 7 other fair value estimates on Nuvation Bio - why the stock might be worth less than half the current price!

Build Your Own Nuvation Bio Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Nuvation Bio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nuvation Bio's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.